HPV vaccine recombinant quadrivalent: safety concerns

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1139, 2007-01, pp. : 3-3

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Quadrivalent HPV vaccine immunogenic, safe

By  

Inpharma, Vol. 1, Iss. 1489, 2005-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Sanofi Pasteur MSD's recombinant quadrivalent human papillomavirus (HPV) vaccine [Gardasil] has been launched in 15 EU countries

By  

Inpharma, Vol. 1, Iss. 1575, 2007-01 ,pp. : 23-23

Adis International

Access to resources Recommend Favorite

Quadrivalent HPV vaccine may prevent cervical cancer

By  

Inpharma, Vol. 1, Iss. 1467, 2004-01 ,pp. : 7-7

Adis International

Access to resources Recommend Favorite

Quadrivalent HPV L1 VLP vaccine prevents vulval, vaginal lesions

By  

Inpharma, Vol. 1, Iss. 1589, 2007-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

HPV vaccine safety data reviewed

By  

Reactions Weekly, Vol. 1, Iss. 1234, 2009-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite